GeNeuro SA Profile Avatar - Palmy Investing

GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology
CH, Plan-les-Ouates [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

GeNeuro SA can't present it's latest revenue by geo. area

Revenue By Geographic Areas

GeNeuro SA can't present it's latest revenue by geo. area

Historical Revenue By Segment

Last 3Y, in mil. USD

GeNeuro SA can't present revenue by segment

Historical Revenue By Geographic Area

Last 3Y, in mil. USD

GeNeuro SA can't present revenue by geo. area

End of GNRO.PA's Analysis
CIK: - CUSIP: H33418106 ISIN: CH0308403085 LEI: - UEI: -
Secondary Listings
GNRO.PA has no secondary listings inside our databases.